Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05538091 · ClinicalTrials.gov registry record · Phase 2
Vismodegib Combined With Atezolizumab in Platinum Resistant Ovarian, Fallopian Tube, and Primary Peritoneal Cancer
A Phase 2 study of Platinum-Resistant Fallopian Tube Carcinoma and Platinum-Resistant Primary Peritoneal Carcinoma, sponsored by Ronald Buckanovich.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 48
- Enrollment target
- 1
- Study location
NCT05538091 is a Phase 2 study of Platinum-Resistant Fallopian Tube Carcinoma and Platinum-Resistant Primary Peritoneal Carcinoma that is actively recruiting participants, run by Ronald Buckanovich. The registered enrollment target is 48 participants, roughly in line with the 45-participant average among 10 other Platinum-Resistant Fallopian Tube Carcinoma trials with a reported enrollment target. The trial reports 1 study location across 1 state.
The verdict
NCT05538091, a Phase 2 study of Platinum-Resistant Fallopian Tube Carcinoma and Platinum-Resistant Primary Peritoneal Carcinoma, is actively recruiting participants, sponsored by Ronald Buckanovich.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 48 participants
- Enrollment target
- 1
- Study location
Study Summary
This trial will treat patients with platinum resistant ovarian, fallopian tube or primary peritoneal cancer as defined by a progression free interval within six months of completion of most recent platinum-based treatment with a combination of vismodegib and atezolizumab. Despite recent improvements in treatment of ovarian cancer with the introduction of PARP inhibitors, response rates to therapy in the platinum resistant setting remain dismal with response rates of only 10-20% reported for single agent cytotoxic therapies. Given the poor prognosis and limited treatment options for these patients, this population is considered appropriate for trials of novel therapeutic candidates.
Conditions Studied
Interventions
- DRUG Atezolizumab
- DRUG Vismodegib
Study Locations (1)
Pennsylvania
- UPMC Hillman Cancer Center - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2023-05-15 |
| Est. Completion | 2033-03-17 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05538091
The ClinicalTrials.gov registry entry for NCT05538091 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 45-participant average among 10 other Platinum-Resistant Fallopian Tube Carcinoma trials with a reported enrollment target. The listed sponsor is Ronald Buckanovich, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Platinum-Resistant Fallopian Tube Carcinoma appearing as the primary indexed condition, and to 2 interventions - of which Atezolizumab is the first listed.
NCT05538091 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT05538091 about?
NCT05538091 is a clinical study titled "Vismodegib Combined With Atezolizumab in Platinum Resistant Ovarian, Fallopian Tube, and Primary Peritoneal Cancer". This trial will treat patients with platinum resistant ovarian, fallopian tube or primary peritoneal cancer as defined by a progression free interval within six months of completion of most recent platinum-based treatment with a combination of vismodegib and atezolizumab. Despite recent improvements...
What is the current status of trial NCT05538091?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 48 participants. The study started on 2023-05-15. Estimated completion is 2033-03-17.
What conditions does trial NCT05538091 study?
This clinical trial studies the following conditions: Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, PARP Inhibitor, Hedgehog Inhibitor.
What interventions are being tested in trial NCT05538091?
The interventions under investigation include: Atezolizumab (DRUG), Vismodegib (DRUG).
Who is sponsoring clinical trial NCT05538091?
This trial is sponsored by Ronald Buckanovich, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05538091 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Platinum-Resistant Fallopian Tube Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Lorigerlimab in Participants With Advanced Solid Tumors
RECRUITING · Phase 2
-
PLX038 for Treatment of Metastatic Platinum-resistant Ovarian, Primary Peritoneal, and Fallopian Tube Cancer
RECRUITING · Phase 2
-
ONC201 Plus Weekly Paclitaxel in Patients With Platinum Refractory or Resistant Ovarian Cancer
RECRUITING · Phase 2
-
Bevacizumab and Anetumab Ravtansine or Paclitaxel in Treating Patients With Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Lenvatinib, Pembrolizumab, and Paclitaxel for Treatment of Recurrent Endometrial, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Oncolytic Adenovirus Coding for TNFa and IL2 (TILT-123) With Pembrolizumab or Pembrolizumab (Phase 1a) and Pegylated Liposomal Doxorubicin (Phase 1b) as Treatment for Ovarian Cancer.
RECRUITING · Phase 1
Explore more on PlainTrial
Platinum-Resistant Fallopian Tube Carcinoma
All registered trials for this condition
Platinum-Resistant Primary Peritoneal Carcinoma
All registered trials for this condition
Pennsylvania
All trials with a study site in Pennsylvania
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.